Literature DB >> 23542369

The utilization of standardized order sets using AASLD guidelines for patients with suspected cirrhosis and acute gastrointestinal bleeding.

Kunut Kijsirichareanchai1, Saowanee Ngamruengphong, Ariwan Rakvit, Kenneth Nugent, Sreeram Parupudi.   

Abstract

To improve the adherence to AASLD (American Association for the Study of Liver Diseases) guidelines for variceal bleeding, we developed and implemented standardized order sets for gastrointestinal bleeding in our hospital on October 1, 2009. We performed medical record reviews of hospitalized patients with gastrointestinal bleeding with suspected cirrhosis from October 2009 to October 2010 to determine the use of octreotide, prophylactic antibiotics, and endoscopy. We reviewed 300 Medical records and identified 26 patients with suspected cirrhosis and gastrointestinal bleeding who had adequate information to determine whether or not the order set was used. Antibiotic was used in 76% of patients, octreotide was used in 76% of patients, and upper endoscopy was completed in 94% of patients within 24 hours. The use of antibiotics was higher than that used in historical controls in our hospital. Implementation of standardized order sets appears to have improved adherence to standard recommendations. However, larger studies with longer follow-ups are needed to evaluate this effect on clinical outcomes and cost of care.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23542369     DOI: 10.1097/QMH.0b013e31828bc328

Source DB:  PubMed          Journal:  Qual Manag Health Care        ISSN: 1063-8628            Impact factor:   0.926


  2 in total

1.  Improving adherence for management of acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Lindsay Sonstein; Carlos Clark; Susan Seidensticker; Li Zeng; Gulshan Sharma
Journal:  Am J Med       Date:  2014-06-11       Impact factor: 4.965

2.  The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial.

Authors:  Michelle Carbonneau; Ejemai Amaize Eboreime; Ashley Hyde; Denise Campbell-Scherer; Peter Faris; Leah Gramlich; Ross T Tsuyuki; Stephen E Congly; Abdel Aziz Shaheen; Matthew Sadler; Marilyn Zeman; Jude Spiers; Juan G Abraldes; Benjamin Sugars; Winnie Sia; Lee Green; Dalia Abdellatif; Jeffrey P Schaefer; Vijeyakumar Selvarajah; Kaleb Marr; David Ryan; Yolande Westra; Neeja Bakshi; Jayant C Varghese; Puneeta Tandon
Journal:  BMC Health Serv Res       Date:  2020-06-18       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.